Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
Protein Pept Lett
; 24(1): 71-77, 2017.
Article
em En
| MEDLINE
| ID: mdl-27894247
ABSTRACT
Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes mellitus and the leading cause of end stage renal disease. One of the key pathways activated in DN is the polyol pathway, in which glucose is converted to sorbitol (a relatively nonmetabolizable sugar) by the enzyme aldose reductase (AR). Shunting of glucose into this pathway causes disruption to glucose metabolism and subsequently damages the tissues via increased oxidative stress, protein kinase c activation and production of advanced glycation end products (AGE) in the kidney. This review aims to provide a comprehensive overview of the AR enzyme structure, substrate specificity and topology in normal physiology; to elaborate on the deleterious effects of AR activation in DN; and to summarize the potential therapeutic benefits and major challenges associated with AR inhibition in patients with DN.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Aldeído Redutase
/
Nefropatias Diabéticas
/
Inibidores Enzimáticos
Limite:
Humans
Idioma:
En
Revista:
Protein Pept Lett
Ano de publicação:
2017
Tipo de documento:
Article